Are you looking for big returns for your portfolio? Of course you are!
Well, the two ASX shares in this article could be worth a look according to analysts at Macquarie Group Ltd (ASX: MQG).
In fact, they believe that these shares could deliver 20% return over the next 12 months. Let's see what it is recommending:
Image source: Getty Images
Siteminder Ltd (ASX: SDR)
This hotel technology company impressed Macquarie with its FY 2025 results and is feeling confident about its prospects in the new financial year. Especially given how strong its annualised recurring revenue (ARR) was. It said:
ARR of $273m has largely derisked FY26 revenue expectations for c$282m, and should accelerate further into FY26 as Smart Platform ramps up. CC ARR growth of +27% accelerated from +22% in 1H25 due to: 1) an improvement in 2H25 sub rev growth; and 2) 2H25 Smart Platform contributions of c$4m.
As a result, Macquarie has retained its outperform rating with a vastly improved price target of $8.11 (from $6.09). Based on its current share price of $6.66, this implies potential upside of 22%.
The broker then concludes:
Outperform. Strong FY25 result and FY26 outlook reinforce our view SDR will rapidly grow rev on continued market share growth and transaction product adoption. Smart Platform represents material upside rev potential and, if successfully executed, should support a long-term re-rating.
EBOS Group Ltd (ASX: EBO)
Another ASX share that Macquarie is bullish on following its results release is EBOS Group. It is the largest trans-Tasman healthcare and animal care company.
It notes that its results in FY 2025 were in line with expectations. And while its guidance for FY 2026 was a touch softer than expected, it remains positive. It said:
2HFY25 uEBITDA in line with guidance and market; final DPS small beat versus market, miss for Macq. FY26E uEBITDA of $615-635m (midpoint 4%/6% below BBG mean/ Macq).
Risks around catalysts still look skewed to the upside. Defensive characteristics likely to be questioned post-result, but LT vol data bears out defensive nature of animal/healthcare segments. DC capex in catchup; costs around programme could have been better communicated. Maintain OP.
According to the note, Macquarie has retained its outperform rating on the ASX share with a NZ$39.78 (A$35.84) price target (from NZ$41.72). Based on its current share price, this suggests that upside of 22% is possible between now and this time next year.
